Peringkat dalam Saham
#13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Kapitalisasi Pasar
$93.46M
Perubahan (1 hari)
-0.96%
Perubahan (1 tahun)
-35.23%
Perdagangan Sensorion SA (ALSEN)
Harga ALSEN dengan kapitalisasi pasar B
Kapitalisasi pasar dari Sensorion SA(ALSEN)
Kapitalisasi Pasar: $93.46M
Per July 2026, Sensorion SA memiliki kapitalisasi pasar sebesar $93.46M. Ini menjadikan Sensorion SA sebagai perusahaan 13334th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Sensorion SA dari 2015 hingga 2026
ALSEN dibandingkan dengan 5 teratas stocks paling populer
| Harga ALSEN |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.110T
|
+5,466,937.08%
|
|
|
|
|
$4.631T
|
+4,955,029.08%
|
|
|
|
|
$4.320T
|
+4,622,094.12%
|
|
|
|
|
$2.861T
|
+3,060,667.82%
|
|
|
|
|
$2.639T
|
+2,823,631.51%
|
